Jennifer Phillips, PhD, is a seasoned oncology leader with expertise in prostate cancer and a strong commitment to patient-centered care. As Group Medical Director at J&J Innovative Medicine, she leads strategic initiatives that bridge clinical research, medical affairs, and patient advocacy. Her work focuses on advancing therapeutic innovation, improving patient outcomes, and fostering inclusive engagement across diverse communities.
Jennifer has actively participated in national forums where she has contributed to discussions on genetic testing, patient education, and health equity.
She collaborates closely with advocacy groups, professional societies and academic institutions to promote precision medicine and ensure that patient voices are central to clinical development and communication strategies.
She has a PhD in pharmacology from the University of Pennsylvania and has been involved in drug development including the approvals of Promacta, Arzerra, and Balversa.
Her personal journey, including the loss of both her grandfather and uncle to prostate cancer and her sister to colorectal cancer, fuels her passion for advancing oncology care and amplifying the impact of patient advocacy.
Jennifer’s leadership continues to shape meaningful partnerships and drive forward the mission of access and informed decision-making in prostate cancer treatment.